产品中心 药物靶点和Fc受体 小分子药物靶点蛋白

所有图片(1/1)

KRAS(Q61H) His Tag Protein, Human

K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,GTPase KRas,KRAS2,RASK2

价格 1,490.00 供应商现货 : 3-5个工作日
货号 UA085050
规格
数量
收藏 分享

产品介绍 评论(0)

产品规格
  • 物种

    Human
  • 分子别名

    K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, KRAS2, RASK2
  • Accession

    P01116-2
  • 表达序列

    Thr2-Cys185(Q61H) with His Tag at the C-Terminus

  • 表达宿主

    E.coli
  • 分子量

    15-25kDa (Reducing)

  • 纯度

    >90% by SDS-PAGE
  • 活性

    The specific activity of KRAS(Q61H) His Tag Protein, Human was determined to be > 290 pmol/min/mg in a GTPase-Glo assay using GTP solution substrate.
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Liquid
  • 缓冲体系

    50mM Tris, 200mM NaCl, 20% Glycerol, 1mM DTT, PH7.5

  • 储存条件

    Stable for 12 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.

  • 文献引用

    1. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M, Wittinghofer A, Ahmadian MR. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat. 2011 Jan;32(1):33-43.
    2. Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 2014 Mar 12;3:e02313.
    3. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3.

背景介绍
  • KRAS is a small GTPase protein located at the inner cell membrane, functioning as a molecular switch that regulates cell proliferation and survival signals. The Q61H mutation resides in the Switch II region, impairing GTPase activity and locking the protein in a constitutively GTP-bound "active" state, leading to aberrant activation of MAPK/PI3K pathways. This mutation is commonly found in pancreatic, colorectal, and non-small cell lung cancers. Compared to KRAS G12 mutations, Q61H exhibits resistance to SHP2 inhibitors and is associated with worse prognosis. Clinical detection of this mutation provides crucial guidance for targeted therapy selection and prognostic evaluation.

操作步骤
  • 实验方法

    实验原理:GTPase Glo™ 检测法通过检测KRAS反应中GTP水解后剩余的GTP量来评估KRAS活性。

    实验材料

    1.KRAS(Q61H) His Tag Protein, Human

    2.GTPase Glo™ Assay (Promega, Catalog # V7681T)

    3.Solid white multi-well plate (384-well plate) (Corning, Catalog #3572)

    4.Plate Reader (PerkinElmer)

    实验步骤

    1.使用GTPase/GAP Buffer配制包含10 µM GTP和2 mM DTT 的2X GTP溶液。

    2.将KRAS用GTPase/GAP Buffer稀释至100 µg/mL、80 µg/mL和60 µg/mL,然后分别向384孔板的每个孔中加入5 µL。

    3.向每个孔中加入5 µL步骤1中配制的2X GTP溶液以启动反应。使用5 µL GTPase/GAP Buffer与2X GTP溶液作为空白对照。反应总体积为10 µL。

    4.室温(22-25℃)下孵育反应30分钟。

    5.轻轻颠倒混匀解冻后的GTPase Glo™ Reagent, 500X,请勿涡旋振荡。根据需要,按比例增减下述成分的体积,配制所需体积的复溶GTPase Glo™ Reagent。

    Sample Name

    Amount

    GTPase Glo ™ Reagent, 500X

    2 μL

    ADP, 10 mM

    0.5 μL

    GTPase Glo ™ Buffer

    998 μL

    Total volume

    1 mL


    6.向完成反应的反应体系中加入10 µL复溶后的GTPase-Glo™ Reagent,短暂混匀后,在室温(22–25°C)下震荡孵育30分钟。

    7.加入20 µL检测试剂,将酶标板在室温(22–25°C)下孵育5–10分钟。

    8.分别在发射波长555 nm(luminescence)下以终点模式读数。

    9.计算比活性。

    Specific Activity (pmol/min/μg) =

    (1-Sample OD/BLANK OD)*50pmol

    Incubation time(min) ×amount of enzyme (μg)


    样品OD值:剩余ATP的OD值

    空白OD值:添加GTP的OD值

    50 pmol:添加的GTP量

    孵育时间:30分钟

    酶量:0.5 μg、0.4 μg和0.3 μg

  • 电泳

    • 1μg (R: reducing condition, N:non-reducing condition).

评论(0)